Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ME2 | P23368 | 2/20 | 0.49 |
| ▸ | ME1 | P48163 | 2/20 | 0.49 |
| ▸ | ME3 | Q16798 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.47 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16397570 | 0.83 | PANK3 (0.57) | PANK3ME2ME1ME3CNR2 | |
| SCHEMBL18711280 | 0.82 | PANK3 (0.60) | PANK3ME2ME1ME3CNR2 | |
| SCHEMBL21520431 | 0.80 | MAPT (0.50) | JAK3KDM4ETET3KMT2AFBXL19 | |
| SCHEMBL1904981 | 0.79 | ME2 (0.58) | PANK3ME2ME1ME3CNR2 | |
| SCHEMBL21521218 | 0.79 | PANK3 (0.58) | PANK3JAK3CNR2 | |
| SCHEMBL21521509 | 0.79 | SMN1; SMN2 (0.64) | PANK3KDM4EKMT2A | |
| SCHEMBL18701794 | 0.78 | PANK3 (0.56) | PANK3KDM4EME2ME1ME3 | |
| SCHEMBL8233183 | 0.78 | ME2 (0.57) | PANK3ME2ME1ME3CNR2 | |
| SCHEMBL17640808 | 0.78 | CNR2 (0.50) | JAK3ME2ME1ME3CNR2 | |
| SCHEMBL20964676 | 0.77 | PANK3 (0.52) | PANK3ME2ME1ME3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | PANK3 165/4885JAK3 2263/4885KDM4E 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.